GlassScriptPhysician profile
Eric J Storvick
NPI 1841279833
$1,182.33
in general payments reported to CMS, 2019-2025
38 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.90 · 2020: $330 · 2021: $11.62 · 2022: $75.09 · 2023: $137 · 2024: $247 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $261.62 | 2020-2021 | |
| Travere Therapeutics, INC. | $83.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $58.01 | 2020-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $51.47 | 2022-2024 | |
| Dexcom, INC. | $47.44 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $45.49 | 2024-2025 | Repatha, Otezla, Tavneos |
| Abbott Laboratories | $42.24 | 2023-2024 | Freestyle Libre 3 |
| Abiomed | $39.87 | 2025 | |
| Daiichi Sankyo INC. | $37.96 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $30.13 | 2024-2025 | Nucala, Shingrix |
| Aurinia Pharma U.S., INC. | $29.61 | 2022-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $28.57 | 2019-2023 | |
| Grifols USA, LLC | $25.31 | 2020-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $25.28 | 2019-2023 | |
| Philips North America LLC | $23.97 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Storvick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.